John Q. Trojanowski

TL;DR: MT-stabilizing drugs could have therapeutic potential for treating neurodegenerative tauopathies by offsetting losses of tau function that result from the sequestration of this MT-st stabilizing protein into filamentous inclusions.

TL;DR: A dinucleotide repeat polymorphism in a tau intron was identified and used in a case-control study to analyze the genetic association of tau with several neurodegenerative diseases with tau pathology as discussed by the authors.

TL;DR: The results demonstrate a differential distribution and course of intra- and extra-cellular AD-like changes during the acute phase following severe TBI in humans, and provide insight into the molecular mechanisms that initiate these pathological cascades very early during severe brain injury.

TL;DR: The data imply that increased age and APOE ɛ4 status are risk factors for co-pathologies independent of neurodegenerative disease; that neurodegenersative disease severity influences co- Pathology as evidenced by the prevalence of co- pathology in high Alzheimer's disease and neocortical Lewy body disease, but not intermediate Alzheimer’s disease or limbic LewyBody disease.

TL;DR: Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration : consensus recommendations